Tag: monoclonal antibodies in veterinary health industry market growth

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Monoclonal Antibodies In Veterinary Health Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The monoclonal antibodies in veterinary health market size has experienced rapid expansion in recent years. This market is projected to increase from $0.92 billion in 2025 to $1.06 billion in 2026, at a compound annual growth rate (CAGR) of 15.2%. The historical growth can be attributed to the rising prevalence of canine cancers, the increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the expansion of veterinary hospitals, and a greater awareness of advanced veterinary treatments.

The monoclonal antibodies in veterinary health market is expected to witness substantial expansion over the next few years. It is projected to grow to $1.85 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.8%. This growth during the forecast period can be attributed to several factors, including technological advancements in mAb engineering, a rising adoption of species-specific therapies, increased investment in veterinary oncology and dermatology, the expansion of personalized veterinary medicine, and the strengthening of the global veterinary healthcare infrastructure. Significant trends anticipated in this period encompass the increase in monoclonal antibody-based treatments for canine cancer, a growing utilization of mabs for autoimmune disorders in dogs, broader application in veterinary dermatology, a surge in the adoption of targeted pain management therapies, and the creation of species-specific antibody treatments for cats, horses, and livestock.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=20575&type=smp&name=Monoclonal%20Antibodies%20In%20Veterinary%20Health%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Monoclonal Antibodies In Veterinary Health Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of animal diseases is projected to drive the expansion of the monoclonal antibodies in veterinary health market in the future. This escalation in animal disease cases stems from more intensive farming methods, heightening the risk of infectious disease propagation, alongside climate change, which broadens the habitats of disease-carrying agents like ticks and mosquitoes. Monoclonal antibodies prove very effective in addressing animal ailments because they precisely target particular pathogens or proteins central to disease mechanisms, providing accurate and potent therapeutic solutions. For example, a report released by GOV.UK, a UK-based government website, in June 2024, revealed that from April 2023 to March 2024, the number of animals slaughtered due to TB incidents increased by 5% in England, reaching 21,298, and by 17% in Wales, to 11,197. Consequently, the escalating animal disease incidences are clearly fueling the growth of the monoclonal antibodies in veterinary health market.

Monoclonal Antibodies In Veterinary Health Market Segment Landscape And Growth Outlook

The monoclonal antibodies in veterinary health market covered in this report is segmented –

1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products

2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals

3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications

4) By Route Of Administration: Injectable, Oral, Topical

5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs

2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Monoclonal Antibodies In Veterinary Health Market Trends Powering Strategic Industry Growth

Major companies operating within the monoclonal antibodies in veterinary health market are concentrating on creating innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatment, to tackle ailments like chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment refers to a therapeutic approach that involves targeting and inhibiting nerve growth factor (NGF) to alleviate pain and inflammation in animals experiencing chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, gained FDA approvals for Librela (bedinvetmab injection), which is the initial monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, administered as a once-monthly injection. Additionally, they secured approval for Apoquel Chewable, the first chewable medication specifically designed for managing allergic itch and inflammation in dogs aged one year or older. Librela itself is a monoclonal antibody engineered to target and inhibit nerve growth factor (NGF). By blocking NGF, Librela helps prevent these pain signals from reaching the brain, consequently reducing the sensation of pain in dogs afflicted with osteoarthritis. Librela represents a notable advancement in veterinary pain management, introducing a novel method for addressing chronic pain in dogs.

Monoclonal Antibodies In Veterinary Health Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell

View The Full Monoclonal Antibodies In Veterinary Health Market Report:

https://thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Monoclonal Antibodies In Veterinary Health Market Geographic Distribution And Regional Opportunities

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Monoclonal Antibodies In Veterinary Health Market In 2026 And How Much Will It Reach By 2030?

The monoclonal antibodies in veterinary health market has experienced substantial growth in recent years. It is forecast to rise from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The expansion observed historically can be ascribed to the rising prevalence of canine cancers, an increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the growth of veterinary hospitals, and a greater awareness of advanced veterinary treatments.

The monoclonal antibodies in veterinary health market is projected for significant expansion in the coming years, anticipated to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.8%. Several factors will drive this growth during the forecast period, including advancements in mAb engineering technology, a greater uptake of species-specific treatments, increased investment in veterinary oncology and dermatology fields, the evolution of personalized veterinary medicine, and the expansion of the global veterinary healthcare infrastructure. Key trends foreseen for the forecast period encompass an increase in monoclonal antibody-based treatments for canine cancer, a surge in the application of mAbs for autoimmune conditions in dogs, broader use of veterinary dermatology applications, enhanced adoption of targeted pain management solutions, and the creation of species-specific antibody therapies tailored for cats, horses, and livestock.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

What Key Growth Drivers Are Influencing The Monoclonal Antibodies In Veterinary Health Market?

The rising animal disease incidences are expected to propel the growth of the monoclonal antibodies in veterinary health market going forward. The rising incidence of animal diseases is driven by intensified farming practices, which increase the risk of infectious disease spread, and climate change, which expands the range of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are highly useful for treating animal diseases as they target specific pathogens or proteins involved in disease processes, offering precise and effective treatments. For instance, in June 2024, according to a report published by the GOV.UK, a UK-based government website, between April 2023 and March 2024, the number of animals slaughtered due to TB incidents rose by 5% in England to 21,298, and by 17% in Wales to 11,197. The rising animal disease incidences are driving the growth of monoclonal antibodies in veterinary health market.

How Is The Monoclonal Antibodies In Veterinary Health Market Examined Through Segment Analysis?

The monoclonal antibodies in veterinary health market covered in this report is segmented –

1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products

2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals

3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications

4) By Route Of Administration: Injectable, Oral, Topical

5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs

2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

What Trends Are Shaping The Monoclonal Antibodies In Veterinary Health Market Structure?

Major companies operating in the monoclonal antibodies in veterinary health market are focusing on developing innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatment to address conditions such as chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment refers to a therapeutic approach that targets and inhibits nerve growth factor (NGF) to reduce pain and inflammation in animals suffering from chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, received FDA approvals for Librela (bedinvetmab injection), the first monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, which is administered as a once-monthly injection, and Apoquel Chewable, the first chewable medication specifically for managing allergic itch and inflammation in dogs aged one year or older. Librela is a monoclonal antibody that targets and inhibits nerve growth factor (NGF). By blocking NGF, Librela helps to prevent these pain signals from reaching the brain, thereby reducing the sensation of pain in dogs with osteoarthritis. Librela represents a significant advancement in veterinary pain management, providing a novel approach to treating chronic pain in dogs.

Which Companies Are Influencing The Monoclonal Antibodies In Veterinary Health Market?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access The Complete Monoclonal Antibodies In Veterinary Health Market Report:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

Which Geographic Region Represents The Largest Monoclonal Antibodies In Veterinary Health Market Share?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Monoclonal Antibodies In Veterinary Health Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Monoclonal Antibodies In Veterinary Health Market In 2026 And How Much Will It Reach By 2030?

The monoclonal antibodies in veterinary health market has experienced substantial growth in recent years. It is forecast to rise from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The expansion observed historically can be ascribed to the rising prevalence of canine cancers, an increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the growth of veterinary hospitals, and a greater awareness of advanced veterinary treatments.

The monoclonal antibodies in veterinary health market is projected for significant expansion in the coming years, anticipated to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.8%. Several factors will drive this growth during the forecast period, including advancements in mAb engineering technology, a greater uptake of species-specific treatments, increased investment in veterinary oncology and dermatology fields, the evolution of personalized veterinary medicine, and the expansion of the global veterinary healthcare infrastructure. Key trends foreseen for the forecast period encompass an increase in monoclonal antibody-based treatments for canine cancer, a surge in the application of mAbs for autoimmune conditions in dogs, broader use of veterinary dermatology applications, enhanced adoption of targeted pain management solutions, and the creation of species-specific antibody therapies tailored for cats, horses, and livestock.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

What Key Growth Drivers Are Influencing The Monoclonal Antibodies In Veterinary Health Market?

The rising animal disease incidences are expected to propel the growth of the monoclonal antibodies in veterinary health market going forward. The rising incidence of animal diseases is driven by intensified farming practices, which increase the risk of infectious disease spread, and climate change, which expands the range of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are highly useful for treating animal diseases as they target specific pathogens or proteins involved in disease processes, offering precise and effective treatments. For instance, in June 2024, according to a report published by the GOV.UK, a UK-based government website, between April 2023 and March 2024, the number of animals slaughtered due to TB incidents rose by 5% in England to 21,298, and by 17% in Wales to 11,197. The rising animal disease incidences are driving the growth of monoclonal antibodies in veterinary health market.

How Is The Monoclonal Antibodies In Veterinary Health Market Examined Through Segment Analysis?

The monoclonal antibodies in veterinary health market covered in this report is segmented –

1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products

2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals

3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications

4) By Route Of Administration: Injectable, Oral, Topical

5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs

2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

What Trends Are Shaping The Monoclonal Antibodies In Veterinary Health Market Structure?

Major companies operating in the monoclonal antibodies in veterinary health market are focusing on developing innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatment to address conditions such as chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment refers to a therapeutic approach that targets and inhibits nerve growth factor (NGF) to reduce pain and inflammation in animals suffering from chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, received FDA approvals for Librela (bedinvetmab injection), the first monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, which is administered as a once-monthly injection, and Apoquel Chewable, the first chewable medication specifically for managing allergic itch and inflammation in dogs aged one year or older. Librela is a monoclonal antibody that targets and inhibits nerve growth factor (NGF). By blocking NGF, Librela helps to prevent these pain signals from reaching the brain, thereby reducing the sensation of pain in dogs with osteoarthritis. Librela represents a significant advancement in veterinary pain management, providing a novel approach to treating chronic pain in dogs.

Which Companies Are Influencing The Monoclonal Antibodies In Veterinary Health Market?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access The Complete Monoclonal Antibodies In Veterinary Health Market Report:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

Which Geographic Region Represents The Largest Monoclonal Antibodies In Veterinary Health Market Share?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Monoclonal Antibodies In Veterinary Health Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Antibacterial Silver Spray Market By 2030 Starting From Its 2026 Size?

The market size for monoclonal antibodies in veterinary health has experienced significant expansion recently. It is projected to increase from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The historical growth in this sector can be attributed to the rising prevalence of canine cancers, an increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the expansion of veterinary hospitals, and a greater awareness of advanced veterinary treatments.

The monoclonal antibodies in veterinary health market is anticipated to experience significant expansion in the foreseeable future. This market is projected to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.8%. This projected increase can be attributed to several factors such as technological advancements in mAb engineering, the growing adoption of species-specific therapies, escalating investment in veterinary oncology and dermatology, the proliferation of personalized veterinary medicine, and the expanding global veterinary healthcare infrastructure. Prominent trends expected during this forecast period include the rise of monoclonal antibody-based treatments for canine cancer, increased utilization of mAbs for autoimmune disorders in dogs, the broadening of veterinary dermatology applications, a greater uptake of targeted pain management therapies, and the ongoing development of species-specific antibody therapies for cats, horses, and livestock.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

What Primary Drivers Are Shaping The Development Of The Antibacterial Silver Spray Market?

Future expansion of the monoclonal antibodies in veterinary health market is anticipated due to an increase in animal disease occurrences. This surge in animal disease frequency stems from intensified agricultural methods, which elevate the potential for infectious disease transmission, and global warming, which broadens the habitat of disease carriers like ticks and mosquitoes. Monoclonal antibodies prove highly effective in managing animal illnesses because they precisely target particular pathogens or proteins engaged in disease mechanisms, thus providing accurate and impactful therapies. An illustrative example comes from a June 2024 report by GOV.UK, a UK-based government website, which revealed that between April 2023 and March 2024, the count of animals culled due to TB incidents climbed by 5% in England, reaching 21,298, and by 17% in Wales, totaling 11,197. Consequently, the increasing occurrences of animal diseases are propelling the expansion of the monoclonal antibodies in veterinary health market.

Which Segment Categories Define The Antibacterial Silver Spray Market?

The monoclonal antibodies in veterinary health market covered in this report is segmented –

1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products

2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals

3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications

4) By Route Of Administration: Injectable, Oral, Topical

5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs

2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

What Major Market Trends Are Driving Changes In The Monoclonal Antibodies In Veterinary Health Market?

Leading companies in the monoclonal antibodies in veterinary health market are concentrating on creating innovative therapeutic solutions for animals, including anti-NGF monoclonal antibody treatments, to manage issues like chronic pain and inflammation. An anti-NGF monoclonal antibody treatment is a therapeutic strategy that targets and inhibits nerve growth factor (NGF) to lessen pain and inflammation in animals experiencing chronic pain conditions. For example, in May 2023, Zoetis, a US-based animal health company, obtained FDA approvals for Librela (bedinvetmab injection), which is the first monoclonal antibody treatment for managing pain linked to osteoarthritis (OA) in dogs, given as a once-monthly injection, and also for Apoquel Chewable, the initial chewable medication specifically for addressing allergic itch and inflammation in dogs aged one year or older. Librela functions as a monoclonal antibody that precisely targets and inhibits nerve growth factor (NGF). By obstructing NGF, Librela assists in preventing pain signals from reaching the brain, thereby decreasing the perception of pain in dogs with osteoarthritis. Librela signifies a major breakthrough in veterinary pain management, offering a new method for treating chronic pain in dogs.

Who Are The Top Companies Competing In The Antibacterial Silver Spray Market?

Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell

Read the full monoclonal antibodies in veterinary health market report here:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

How Does The Antibacterial Silver Spray Market Perform Across Major Global Regions?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antibacterial Silver Spray Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp

Browse Through More Reports Similar to the Global Monoclonal Antibodies In Veterinary Health Market 2026, By The Business Research Company

Veterinary Reference Laboratory Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-reference-laboratory-global-market-report

Veterinary Stereotactic Radiosurgery System Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-stereotactic-radiosurgery-system-global-market-report

Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-active-pharmaceutical-ingredients-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cell therapy manufacturing automation market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Monoclonal Antibodies In Veterinary Health Market size between 2026 and 2035?

The monoclonal antibodies in veterinary health market has shown significant expansion over recent years. It is forecast to increase from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. Historically, this market’s expansion was propelled by factors such as the growing occurrence of canine cancers, an uptick in autoimmune disorders among pets, a limited supply of specific targeted therapies, the proliferation of veterinary hospitals, and heightened recognition of sophisticated veterinary treatments.

The monoclonal antibodies in veterinary health market is projected to experience substantial growth over the coming years, reaching $1.85 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.8%. This expansion during the forecast period is fueled by several factors, including technological innovations in mAb engineering, the growing uptake of species-specific treatments, increased investments in veterinary oncology and dermatology, the rise of personalized veterinary medicine, and the broader development of global veterinary healthcare infrastructure. Key trends expected during this period involve the proliferation of monoclonal antibody-based treatments for canine cancer, the increasing application of mabs for autoimmune conditions in dogs, the broadening scope of veterinary dermatology uses, a greater embrace of targeted pain management solutions, and the creation of species-specific antibody therapies for cats, horses, and livestock.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

Which Drivers Are Impacting Market Performance In The Monoclonal Antibodies In Veterinary Health Market?

An escalation in animal disease occurrences is projected to stimulate the expansion of the monoclonal antibodies in veterinary health market going forward. This heightened frequency of animal diseases is fueled by intensive farming practices, which elevate the potential for infectious disease transmission, as well as by climate change, which broadens the territories of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are notably effective for addressing animal ailments since they pinpoint particular pathogens or proteins engaged in disease processes, thus delivering accurate and potent therapies. For example, in June 2024, a report released by GOV.UK, a UK-based government website, indicated that from April 2023 to March 2024, the quantity of animals culled due to TB incidents saw a 5% increase in England, reaching 21,298, and a 17% increase in Wales, reaching 11,197. Consequently, the rising animal disease incidences are propelling the growth of the monoclonal antibodies in veterinary health market.

Which Segments Are Contributing To The Growth Of The Monoclonal Antibodies In Veterinary Health Market?

The monoclonal antibodies in veterinary health market covered in this report is segmented –

1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products

2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals

3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications

4) By Route Of Administration: Injectable, Oral, Topical

5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs

2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

What Trends Are Projected To Support The Growth Of The Monoclonal Antibodies In Veterinary Health Market?

Leading companies within the monoclonal antibodies in veterinary health market are dedicated to creating advanced veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatments designed to alleviate chronic pain and inflammation in animals. This anti-NGF monoclonal antibody treatment functions by targeting and inhibiting nerve growth factor (NGF) to lessen discomfort and inflammation in animals experiencing persistent pain conditions. For example, in May 2023, Zoetis, a US-based animal health company, obtained FDA clearances for Librela (bedinvetmab injection), the initial monoclonal antibody treatment for controlling pain linked with osteoarthritis (OA) in dogs, administered via a once-monthly injection, and Apoquel Chewable, the inaugural chewable medication specifically formulated for managing allergic itch and inflammation in dogs aged one year or older. Librela is a monoclonal antibody that specifically targets and inhibits nerve growth factor (NGF). By obstructing NGF, Librela effectively prevents these pain signals from reaching the brain, thereby diminishing the sensation of pain in dogs afflicted with osteoarthritis. Librela signifies a considerable leap forward in veterinary pain management, offering an innovative method for treating chronic pain in dogs.

Who Are The Top-Performing Companies In The Monoclonal Antibodies In Veterinary Health Market In Recent Years?

Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

Which Region Currently Holds The Largest Share Of The Monoclonal Antibodies In Veterinary Health Market?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Monoclonal Antibodies In Veterinary Health Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp

Browse Through More Reports Similar to the Global Monoclonal Antibodies In Veterinary Health Market 2026, By The Business Research Company

Veterinary Reference Laboratory Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-reference-laboratory-global-market-report

Veterinary Stereotactic Radiosurgery System Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-stereotactic-radiosurgery-system-global-market-report

Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-active-pharmaceutical-ingredients-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Discover trends, market shifts, and competitive outlooks for the monoclonal antibodies in veterinary health industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Monoclonal Antibodies In Veterinary Health Market Expected to Grow Between 2025 And 2029?

The market of monoclonal antibodies for veterinary health has seen a significant expansion in the recent past. It is projected to escalate from a size of $0.8 billion in 2024 up to $0.92 billion in 2025, marking a remarkable CAGR of 15.2%. Factors such as the rise in the global ownership of pets, the occurrence of long-term illnesses in animals, a surge in pet adoption and heightened health awareness amongst pet proprietors have led to this growth during the historic period.

In the coming years, the market for monoclonal antibodies in veterinary health is predicted to experience swift expansion. It is projected to reach $1.61 billion by 2029 with a compound annual growth rate (CAGR) of 15.0%. The upswing estimated within the forecast period is due to an escalating pet population, heightened pet expenses, an increasing incidence of canine atopic dermatitis, higher demand for advanced veterinary healthcare, and a growing emphasis on animal health. Future trends predicted for this period include progress in biotechnology and research, advancements in genetic engineering, innovative animal treatments, breakthroughs in antibody-based therapies, and technological progress in antibody engineering.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

What Are the Core Growth Drivers Propelling the Monoclonal Antibodies In Veterinary Health Market Forward?

An increase in instances of animal disease is anticipated to boost the expansion of the monoclonal antibodies in the veterinary health market. Intensified farming practices, resulting in a higher risk of spreading infectious diseases, and climate change, which broadens the habitat of disease-carrying insects like ticks and mosquitoes, lead to a surge in animal diseases. Monoclonal antibodies are optimal for treating these diseases because they focus on specific pathogens or proteins involved in the disease, providing accurate and potent treatments. For example, a report by GOV.UK, a government website in the UK, published in June 2024, shared that the number of animals culled as a result of TB incidents increased by 5% to 21,298 in England, and 17% to 11,197 in Wales, from April 2023 to March 2024. Therefore, the increasing incidences of animal disease are fueling the growth of the veterinary health market’s monoclonal antibodies.

What Segment Types Define the Monoclonal Antibodies In Veterinary Health Market Structure?

The monoclonal antibodies in veterinary health market covered in this report is segmented –

1) By Animal Type: Dogs, Other Animal Types

2) By Application: Dermatology, Pain, Other Applications

3) By End-User: Veterinary Hospitals, Other End-Users

Subsegments:

1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies

2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Monoclonal Antibodies In Veterinary Health Market?

North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Monoclonal Antibodies In Veterinary Health Market?

Leading firms in the market for monoclonal antibodies in veterinary health are concentrating on the development of revolutionary veterinary therapeutics, such as anti-NGF monoclonal antibody treatment for issues like chronic animal discomfort and swelling. This treatment strategy aims at targeting and blocking nerve growth factor (NGF) to alleviate pain and inflammation in animals who suffer from chronic pain conditions. For example, in May 2023, Zoetis, an American animal health organization, earned FDA approval for Librela (bedinvetmab injection), the inaugural monoclonal antibody therapy designed to manage osteoarthritis (OA) related pain in dogs, through a once a month injection, and for Apoquel Chewable, which is the first chewable medicine designed for the treatment of allergic itch and inflammation for dogs aged one year or older. Librela is an antibody that targets and inhibits nerve growth factor (NGF). By intercepting NGF, Librela can interrupt pain signals before they reach the brain, hence reducing the feeling of pain in dogs with osteoarthritis. This novel therapy represents a substantial development in the field of veterinary pain management for dogs suffering from chronic pain.

View the full report here:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

What Is the Definition of the Monoclonal Antibodies In Veterinary Health Market?

Monoclonal antibodies in veterinary health are specialized proteins engineered to target and neutralize specific pathogens or toxins in animals, aiding in the diagnosis and treatment of various diseases. They are created by cloning a single type of immune cell to produce identical antibodies that precisely bind to their target.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20575

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model